idrabiotaparinux

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
02420082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Idrabiotaparinux, a long-acting inhibitor of factor Xa, was shown to be effective in the treatment of patients with… (More)
Is this relevant?
2013
2013
AIM To assess the bioequipotency of equimolar doses of idraparinux (2.5 mg) and idrabiotaparinux (3.0 mg). METHOD In a phase I… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Review
2013
Review
2013
BACKGROUND Venous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and… (More)
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
as a once-weekly subcutaneous injection. Another benefit of idrabiotaparinux is that it contains a biotin moiety, which allows… (More)
Is this relevant?
2010
2010
BACKGROUND Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2010
2010
Thromboembolic disorders are one of the disorders for which we are still on the look out for a safe and efficient drug. Despite… (More)
Is this relevant?
2009
2009
BACKGROUND Idraparinux, a long-acting synthetic pentasaccharide, is a specific antithrombin-dependent inhibitor of activated… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2009
Review
2009
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?